Novartis named first-ever corporate pharmaceutical partner of the NFL
See how this partnership is turning fan passion into health prevention and enabling better health in our communities.
Discover our medicines
See how our innovative medicines are addressing society's greatest health challenges.
Commitment to patients
From research and development to expanding access, uncover our commitment to improving people's lives.
Inspired by purpose
Learn about our people and culture, and how we're driven by our mission to reimagine medicine.
Novartis Financial Results - Q1 2025
Novartis announced the company’s financial results for the first quarter of 2025.
Latest News
Novartis plans to expand its US-based manufacturing and R&D footprint with a total investment of $23B over the next 5 years
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
